Gliomas are the most common brain-derived neoplasms with glioblastoma (GBM) multiforme being the most frequent and also the most malignant subtype.
Of these, more than half are Glioblastomas (GBM), which is the most malignant subtype and are normally treated with surgery, followed by radiotherapy and chemotherapy with Temozolomide (TMZ) [ 2, 3].
For example, patients with the most malignant histopathologic subtype, glioblastoma (GBM), carry the worst prognosis, with a median survival period of less than 12 months, despite having undergone surgical treatment combined with radiotherapy and chemotherapy [ 2].
Out of these thirty patients, squamous cell carcinoma (16 cases; 53.33%) was the most common malignant subtype followed by adenocarcinoma (9 cases; 30%), small cell carcinoma (4 cases; 13.33%), and undifferentiated carcinoma (1 case; 3.33%).
Recent advances in novel drug development strategies have improved treatment paradigms for hormone-sensitive and HER2 overexpressing breast cancers; however, the most malignant and heterogeneous subtype, TNBC, remains largely intractable due to an aggressive metastatic character and rapid recurrence after treatment.
The least differentiated and thus the most malignant and aggressive form is the solid subtype, accounting for 10% of ACC cases [12].
Glioblastoma multiforme (GBM), a subtype of gliomas, is the most common and the most malignant glioma (World Health Organization [WHO] grade IV) with median survival of only 12-15 months under the current standard of care [ 3].
Gastric carcinoma is the most malignant tumor.
The most malignant force is Newark's violence.
Gliomas are one of the most malignant cancers.
